“…Although the effects of both NO and sGC on cardiac contractile function have been previously examined in a broad range of scenarios, no consensus has yet been reached, with negative inotropic (Balligand et al ., ; Brady et al ., ; Grocott‐Mason et al ., ; Weyrich et al ., ; Mohan et al ., ; Kojda et al ., ; Sandirasegarane and Diamond, ; Muller‐Strahl et al ., ; Gonzalez et al ., ; Cawley et al ., ; Derici et al ., ), positive inotropic (Klabunde and Ritger, ; Smith et al ., ; Kojda et al ., 1995; 1996; 1997; Sarkar et al ., ; Layland et al ., ; Langer et al ., ) or no change observed (Ritchie et al ., 2006; 2009). Indeed, the relationship between NO/sGC and myocardial force may be differentially modulated by concentration, whereby smaller increases in NO/sGC levels elicit positive inotropic effects either secondary to phosphodiesterase‐3 inhibition (elevating cAMP), while high concentrations elicit a cGMP‐mediated negative inotropic effect, perhaps secondary to formation of S‐nitrosothiols on key cardiomyocyte Ca 2+ ‐handling proteins such as RyR, SERCA and phospholamban (Smith et al ., ; Kojda et al ., 1996; 1997; Zahradnikova et al ., ; Paolocci et al ., ; Layland et al ., ; Langer et al ., ; Gonzalez et al ., 2007; 2008; Rastaldo et al ., ; Wang et al ., ; Ziolo, ).…”